Market News

Adverum Biotechnologies, Inc. (ADVM) Reaches $5.33 After 9.00% Down Move; Synbiotics (SBIO)’s Sentiment Is 2.83

The stock of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a huge mover today! The stock decreased 16.14% or $1.025 during the last trading session, reaching $5.325. About 3.50M shares traded or 214.98% up from the average. Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has risen 103.64% since May 6, 2017 and is uptrending. It has outperformed by 92.09% the S&P500.The move comes after 6 months negative chart setup for the $331.39M company. It was reported on May, 6 by Barchart.com. We have $4.85 PT which if reached, will make NASDAQ:ADVM worth $29.83M less.

Synbiotics Corp (SBIO) investors sentiment increased to 2.83 in 2017 Q4. It’s up 1.45, from 1.38 in 2017Q3. The ratio has increased, as 17 active investment managers increased and started new positions, while 6 decreased and sold their equity positions in Synbiotics Corp. The active investment managers in our database now own: 529,771 shares, up from 449,213 shares in 2017Q3. Also, the number of active investment managers holding Synbiotics Corp in top ten positions was flat from 0 to 0 for the same number . Sold All: 1 Reduced: 5 Increased: 9 New Position: 8.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $331.39 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

More notable recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: Globenewswire.com which released: “Adverum Biotechnologies Announces Leadership Changes” on May 03, 2018, also Nasdaq.com with their article: “Adverum Biotechnologies Announces Long-term Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD” published on May 01, 2018, Benzinga.com published: “38 Stocks Moving In Friday’s Mid-Day Session” on May 04, 2018. More interesting news about Adverum Biotechnologies, Inc. (NASDAQ:ADVM) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down” published on May 04, 2018 as well as Seekingalpha.com‘s news article titled: “Adverum Biotechnologies: Gene Therapy Company And Our New Buy” with publication date: April 08, 2018.

Analysts await Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report earnings on May, 8. They expect $-0.29 EPS, up 23.68% or $0.09 from last year’s $-0.38 per share. After $-0.32 actual EPS reported by Adverum Biotechnologies, Inc. for the previous quarter, Wall Street now forecasts -9.38% EPS growth.

Barometer Capital Management Inc. holds 0.23% of its portfolio in ALPS Medical Breakthroughs ETF for 76,100 shares. Ntv Asset Management Llc owns 14,800 shares or 0.14% of their US portfolio. Moreover, Cambridge Trust Co has 0.04% invested in the company for 21,027 shares. The New York-based Virtu Financial Llc has invested 0.04% in the stock. Murphy Capital Management Inc, a New Jersey-based fund reported 7,000 shares.

The ETF increased 1.62% or $0.55 during the last trading session, reaching $34.62. About 21,634 shares traded. ALPS Medical Breakthroughs ETF (SBIO) has risen 31.07% since May 6, 2017 and is uptrending. It has outperformed by 19.52% the S&P500.

Another recent and important ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) news was published by Investorplace.com which published an article titled: “5 Biotech ETFs for Outsized Gains” on April 25, 2018.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *